Itopride HCl API | Gastroprokinetic API Manufacturer in India

Swapnroop Pharma · WHO-GMP Certified · +91 87670 62101

Itopride HCl API

Itopride Hydrochloride (Itopride HCl) is a gastroprokinetic agent used primarily for the management of symptoms associated with impaired gastrointestinal motility. It combines dopamine D₂-receptor antagonism with acetylcholinesterase inhibition, enhancing cholinergic activity in the gastrointestinal tract.

Itopride HCl promotes gastric motility and facilitates gastric emptying, making it relevant to the treatment of functional upper gastrointestinal disorders.

Itopride HCl API Manufacturer in India

Itopride HCl is a specialized gastrointestinal pharmaceutical API manufactured through controlled chemical synthesis, purification and hydrochloride salt formation.

Important quality attributes include identity, assay, related substances, water content, residual solvents, chloride content, residue on ignition and stability.

Chemical Information

CAS Number: 122892-31-3
Molecular Formula: C20H26N2O2·HCl
Molecular Weight: 394.89 g/mol
Drug Class: Gastroprokinetic Agent
Pharmacological Class: Dopamine D₂ Antagonist / Acetylcholinesterase Inhibitor
Therapeutic Class: Gastrointestinal Motility Agent
Therapeutic Area: Gastroenterology

Mechanism of Action

Itopride has a dual mechanism of action:

1. Dopamine D₂-receptor antagonism
It blocks dopamine D₂ receptors in the gastrointestinal tract, reducing dopamine-mediated inhibition of gastrointestinal motility.

2. Acetylcholinesterase inhibition
It inhibits acetylcholinesterase, increasing the availability of acetylcholine at cholinergic nerve endings.

Together, these actions can result in:

  • Increased gastrointestinal motility
  • Enhanced gastric emptying
  • Improved coordination of gastric movement
  • Reduction of gastrointestinal stasis
  • Improvement of selected dyspeptic symptoms

Pharmaceutical Applications

Itopride HCl is primarily used for symptomatic management of upper gastrointestinal motility disorders, including:

  • Functional dyspepsia
  • Postprandial fullness
  • Early satiety
  • Bloating
  • Upper abdominal discomfort
  • Nausea associated with impaired gastric motility

Specific indications depend on the approved formulation and regulatory market.

Gastroprokinetic Characteristics

Itopride differs from conventional dopamine-antagonist prokinetics because it combines D₂ receptor blockade and acetylcholinesterase inhibition.

This pharmacological profile supports its action on gastric motility and gastric emptying.

Manufacturing Process

Typical API manufacturing may involve:

  1. Preparation of substituted benzamide intermediates
  2. Controlled chemical synthesis
  3. Introduction of the piperidine-containing side chain
  4. Purification
  5. Formation of the hydrochloride salt
  6. Crystallization
  7. Filtration
  8. Drying
  9. Milling where required
  10. Final analytical testing
  11. Controlled packaging

Quality and Analytical Testing

Itopride HCl API quality evaluation may include:

  • Identification by IR
  • Identification by HPLC
  • Assay
  • Related substances
  • Organic impurities
  • Water content
  • Chloride content
  • Residual solvents
  • Elemental impurities
  • Residue on ignition
  • Melting range
  • Particle-size distribution where required
  • Stability testing

Storage

Itopride HCl should be stored in a tightly closed container under controlled pharmaceutical storage conditions, protected from excessive heat, moisture and direct light. Final storage requirements should be established from validated stability studies.

Pharmaceutical Research and Development

Itopride HCl is relevant to research involving:

  • Gastroprokinetic agents
  • Gastrointestinal motility
  • Dopamine D₂ receptors
  • Acetylcholinesterase inhibition
  • Gastric emptying
  • Functional dyspepsia
  • Gastrointestinal pharmacology
  • Oral pharmaceutical formulations

Itopride HCl API Summary

Itopride HCl is a gastroprokinetic agent with CAS Number 122892-31-3, molecular formula C20H26N2O2·HCl, and molecular weight 394.89 g/mol. It enhances gastrointestinal motility through combined dopamine D₂-receptor antagonism and acetylcholinesterase inhibition and is primarily associated with functional upper gastrointestinal disorders.

Detailed Specifications

Parameter Specification
Appearance White to off-white crystalline powder
Identification IR & HPLC compliant
Assay (HPLC) 98.0% – 102.0%
Loss on Drying NMT 1.0%
Residue on Ignition NMT 0.5%
Individual Impurity NMT 0.5%
Total Impurities ≤ 1.5%
Water Content NMT 2.0%
Get Bulk Quote via WhatsApp